NVO Stock Alert: Novo Nordisk Pops on New Weight-Loss Drug

Novo Nordisk (NYSE:NVO) stock is soaring higher on Thursday after the pharmaceutical company announced results from a weight loss drug clinical trial.The big news here is the company’s oral weight loss drug amycretin producing 13.1% weight loss in patients after 12 weeks. That’s a major improvement over the 6% weight loss produced by the company’s own injectable drug Wegovy.Following this success, Novo Nordisk has announced plans for a Phase 2 clinical trial of amycretin. The company intends to start this t ...